MeiraGTx is a clinical-stage genetic medicine company developing gene therapies for inherited and acquired diseases, with a strong focus on ocular disorders as well as programs in salivary gland and central nervous system conditions. It builds and operates manufacturing capability for viral vectors, a scarce and strategic asset in gene therapy. Revenue has been limited and often collaboration-driven while late-stage candidates advance toward potential commercialization.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 1.9 | — | -40 | — |
| Q2 2025 | 3.7 | — | -38.8 | — |
| Q3 2025 | 0.4 | — | -50.5 | — |
| Q4 2025 | 75.4 | — | 15.1 | — |
| Q1 2026 | 0.3 | -84.8% | -46.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: First Mid Bancshares, Inc. (FMBH), Integra LifeSciences Holdings Corporation (IART), Corsair Gaming, Inc. (CRSR), Frontier Group Holdings, Inc. (ULCC), PureCycle Technologies, Inc. (PCT), Red Cat Holdings, Inc. (RCAT)